Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy
People Are Sharing How GLP-1 Medications Changed Their Lives For The Better GLP-1 medications like Ozempic, Mounjaro, Wegovy, and Zepbound have dominated the conversation for the last couple of years
This triggers the cAMP signalling cascade, which activates protein kinase A (PKA), leading to hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) activation, resulting in triglyceride hydrolysis in adipocyte cell models
Lipotropic injections are used alongside not as a replacement for a reduced-calorie diet and physical activity
